Clinical Trial Update: A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

View source ↗

Summary

A completed real-world evidence study by Regeneron evaluated the incidence of retinal vasculitis in adults receiving aflibercept 2 mg in the United States.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Vasculitis

Drugs mentioned

• Eylea (aflibercept) (aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Retinal Vasculitis | Status: COMPLETED